Practice Areas

Risperdal and Invega

The antipsychotic drugs Risperdal and Invega have been associated with an increased risk of serious gynecomastia (male breast growth) and excessive weight gain in young men and adult males. Other side effects include involuntary movement disorders, diabetes, breast cancer, lactation, pancreatitis, and osteoporosis. Several scientific studies have found that Risperdal is associated with a significant increase in the risk of gynecomastia and weight gain. If you or a loved one has taken Risperdal or Invega and suffered gynecomastia, weight gain, or any other health problem, contact the Risperdal and Invega attorneys, serving Pennsylvania, New Jersey and New York areas.

About Risperdal and Invega

Risperdal is a dangerous pharmaceutical intended to treat schizophrenia and certain problems caused by bipolar disorder. The drug has also been prescribed to treat autism, dementia, anxiety, depression, attention disorders, and tourette syndrome. Invega is an extended-release derivative of Risperdal and has been shown to cause similar side effects to that of Risperdal.

Risperdal and Invega Lawsuits

There are currently more than 1,000 cases related to Risperdal and Invega ingestion pending in the Philadelphia Court of Common Pleas. To date, the companies have settled cases with individual plaintiffs and several of the cases are scheduled for trial. Many of these cases relate to gynecomastia and weight gain, but the medications’ side effects are not limited to the development of male breasts and weight gain. In October 2013, a study appearing in the Journal of Clinical Psychopharmacology suggests that Americans treated with the antipsychotic Risperdal presented with a 69% increased risk for the development of Risperdal gynecomastia when compared against those who did not take Risperdal.

Johnson & Johnson and its Janssen Pharmaceuticals division are accused of improperly marketing Risperdal for off-label uses. The complaints further allege that the companies engaged in false and misleading promotional activities, negligently designed the medications, failed to warn consumers of the risks of the medications, and breached warranties to consumers. In 2013, Johnson & Johnson agreed to pay more than $2.2 billion in criminal and civil fines to the Department of Justice to settle charges that the defendants improperly promoted the antipsychotic drug Risperdal to older adults, children, and people with developmental disabilities. The agreement was the third-largest pharmaceutical settlement in United States history.

Contact a Locks Law Firm Risperdal and Invega Lawyer

If you or a loved one has taken Risperdal, Invega, or Invega Sustenna and experienced any of the side effects described above, or other health conditions, contact the Locks Law Firm today. Our Pennsylvania, New Jersey and New York attorneys can provide information about filing a Risperdal, Invega, or Invega Sustenna lawsuit during a free, confidential consultation and case evaluation.

Do I have a case? Free Case Evaluation